



HHS Public Access

Author manuscript

Matrix Biol. Author manuscript; available in PMC 2016 February 10.

Published in final edited form as:

Matrix Biol. 2009 May ; 28(4): 194–201. doi:10.1016/j.matbio.2009.02.004.

Developmental distribution of collagen IV isoforms and relevance to ocular diseases

Xiaoyang Bai, David J. Dilworth, Yi-Chinn Weng, and Douglas B. Gould*

Departments of Ophthalmology and Anatomy, Institute of Human Genetics, University of California, San Francisco, CA 94143, United States

Abstract

Type IV collagens are the most abundant proteins in basement membranes. Distinct genes encode each of six isoforms, $\alpha 1(\text{IV})$ through $\alpha 6(\text{IV})$, which assemble into one of three characteristic heterotrimers. Disease-causing mutations in each of the six genes are identified in humans or mice and frequently include diverse ocular pathogenesis that encompass common congenital and progressive blinding diseases, such as optic nerve hypoplasia, glaucoma, and retinal degeneration. Understanding where and when collagen IV molecules are expressed is important because it defines limits for the location and timing of primary pathogenesis. Although localization of collagen IV isoforms in developed human eyes is known, the spatial and temporal distribution of type IV collagens throughout ocular development has not been determined in humans or in mice. Here, we use isoform-specific monoclonal antibodies to systematically reveal the localization of all six collagen IV isoforms in developing mouse eyes. We found that $\alpha 1(\text{IV})$ and $\alpha 2(\text{IV})$ always co-localized and were ubiquitously expressed throughout development. $\alpha 3(\text{IV})$ and $\alpha 4(\text{IV})$ also always co-localized but in a much more spatially and temporally specific manner than $\alpha 1(\text{IV})$ and $\alpha 2(\text{IV})$. $\alpha 5(\text{IV})$ co-localized both with $\alpha 3(\text{IV})/\alpha 4(\text{IV})$, and with $\alpha 6(\text{IV})$, consistent with $\alpha 5(\text{IV})$ involvement in two distinct heterotrimers. $\alpha 5(\text{IV})$ was present in all basement membranes except those of the vasculature. $\alpha 6(\text{IV})$ was not detected in vasculature or in Bruch's membrane, indicating that $\alpha 5(\text{IV})$ in Bruch's membrane is part of the $\alpha 3\alpha 4\alpha 5$ heterotrimer. This comprehensive analysis defines the spatial and temporal distribution of type IV collagen isoforms in the developing eye, and will contribute to understanding the mechanisms underlying collagen IV-related ocular diseases that collectively lead to blindness in millions of people worldwide.

Keywords

Type IV collagen; Basement membrane; Ocular development

1. Introduction

The role for type IV collagens in human diseases is gaining broader appreciation. The variability of diseases caused by mutations in type IV collagen genes is dictated, at least in part, by the distribution of the corresponding protein product. $\alpha 1(\text{IV})$ and $\alpha 2(\text{IV})$ are present in nearly all basement membranes in the body. Mutations in the genes encoding $\alpha 1(\text{IV})$ and

* Corresponding author. Tel.: +1 415 476 3592; fax: +1 415 476 0336, gouldd@vision.ucsf.edu (D.B. Gould).

$\alpha 2(\text{IV})$ were only recently identified and the full breadth of their contribution to disease remains to be discovered (Breedveld et al., 2006; de Vries et al., 2009; Favor et al., 2007; Gould et al., 2005, 2006; Plaisier et al., 2007; Sibon et al., 2007; Vahedi et al., 2007a,b). Ocular anterior dysgenesis is a highly penetrant phenotype in mice with *Col4a1* or *Col4a2* mutations. Mutant mice have ocular anterior segment dysgenesis (ASD) that resembles a spectrum of human phenotypes, including Axenfeld–Rieger Anomaly, which causes secondary glaucoma (Favor et al., 2007; Gould et al., 2007; Van Agtmael et al., 2005). In the posterior eye, *Col4a1* mutation causes optic nerve hypoplasia (Gould et al., 2007) and retinal degeneration (D.B. Gould unpublished results).

Mutations in genes coding for the more spatially restricted $\alpha 3(\text{IV})$, $\alpha 4(\text{IV})$, and $\alpha 5(\text{IV})$ cause Alport syndrome. Alport syndrome is characterized by hematuria, progressive renal impairment, high-tone sensorineural hearing loss, and ocular abnormalities. Ocular abnormalities are highly, but not completely, penetrant. Approximately 70% of patients have thin lens capsules and lenticonus (bulging of the anterior lens), and 50–80% of patients have central or peripheral retinopathy appearing as whitish-yellow dots and flecks (Barker et al., 1990; Chugh et al., 1993; Colville and Savige, 1997; Jacobs et al., 1992; Streeten et al., 1987). Other ocular features including posterior polymorphous corneal dystrophy or macular holes are also reported in rare cases (Colville et al., 1997a). The vast majority of Alport syndrome is X-linked and caused by mutations in *COL4A5*; however, ocular features do not appear to differ between X-linked and autosomal recessive cases (attributed to *COL4A3* or *COL4A4* mutations) (Colville et al., 1997b; Colville and Savige, 1997). To date, mutations in *COL4A6*, alone, are not shown to contribute to disease but mutation of *COL4A6* in combination with *COL4A5* contributes to leiomyomatosis (Cochat et al., 1988; Heidet et al., 1997).

Normal vision requires precise localization and arrangement of several distinct ocular structures. Development of these structures requires coordinated interactions between embryonic tissues, all of which interact with basement membranes. Mutations of basement membrane components lead to ocular dysgenesis; however, the mechanism(s) are unknown (Favor et al., 2007; Gould et al., 2005, 2007; Semina et al., 2006; Sibon et al., 2007; Van Agtmael et al., 2005; Zenker et al., 2004, 2005). In mice, ocular development starts around mid-embryogenesis and proceeds through a series of characteristic morphological stages (Gould et al., 2004; Kaufmann, 2005). By birth, the major ocular structures are formed and ocular basement membranes are in place surrounding the cornea, lens, retina and vasculature (Fig. 1).

Basement membranes are specialized structures of extracellular matrix that play essential roles in tissue development and maintenance, and type IV collagens are abundant components of all basement membranes. Type IV collagens are a family of six proteins encoded by six distinct genes, *COL4A1* through *COL4A6* (Hostikka et al., 1990; Hostikka and Tryggvason, 1988; Leinonen et al., 1994; Mariyama et al., 1994; Soininen et al., 1987; Zhou et al., 1994). They are arranged on chromosomes head-to-head in pairs, with *COL4A1* and *COL4A2* on chromosome 13, *COL4A3* and *COL4A4* on chromosome 2, and *COL4A5* and *COL4A6* on the X chromosome (Hudson et al., 1993; Kuhn, 1995). During assembly in the endoplasmic reticulum, three collagen IV peptides interact to form one of three triple-

helical heterotrimers, $\alpha 1\alpha 1\alpha 2$, $\alpha 3\alpha 4\alpha 5$, or $\alpha 5\alpha 5\alpha 6$ (Borza et al., 2001; Gunwar et al., 1998; Risteli et al., 1980). After secretion, heterotrimers make further, higher-order associations to form mesh-like collagen IV networks and integrate with other components, such as laminin, Nidogen/entactin and perlecan, to form basement membranes (Borza et al., 2001, 2002; Timpl et al., 1981). Distribution and abundance of collagen IV heterotrimers is tissue specific and varies with developmental stages (Hasegawa et al., 2007; Nakano et al., 2007; Saito et al., 2000; Urabe et al., 2002).

To better understand the mechanism(s) of collagen IV-related ocular diseases, we sought to determine the timing and distribution of all six collagen IV isoforms in the developing mouse eye. The timing and location of initial protein expression defines limits for timing and location of primary pathogenesis. To date, only a single study examined the distribution of type IV collagens in the developing human or mouse eye and it focused exclusively on the lens capsule (Kelley et al., 2002). Other reports have studied type IV collagens in the developed human eye but the distribution and timing of expression during development is currently unknown (Chen et al., 2003; Kabosova et al., 2007; Schlotzer-Schrehardt et al., 2007). By only studying already-developed and adult organs, one could overlook important biological and disease-related processes. Equally important as stage-specific differences are species-specific differences. Distribution differences between humans and mice will be important to identify and define as mouse models are increasingly used to understand collagen IV-related human ocular diseases. Here, we define the localization of collagen IV isoforms in the developing mouse eye.

2. Results

2.1. Differential distribution of type IV collagens in the developing eye

To examine the distributions of all six collagen IV isoforms in developing eyes, we labeled eyes from various embryonic and postnatal stages with monoclonal antibodies against each isoform (Sado et al., 1995). We found that $\alpha 1(\text{IV})$ always co-localized with $\alpha 2(\text{IV})$ and that $\alpha 3(\text{IV})$ always co-localized with $\alpha 4(\text{IV})$, whereas $\alpha 5(\text{IV})$ colocalized both with $\alpha 3(\text{IV})/\alpha 4(\text{IV})$ and with $\alpha 6(\text{IV})$ (Table 1). This is consistent with the existence of three types of heterotrimers, $\alpha 1\alpha 1\alpha 2$, $\alpha 3\alpha 4\alpha 5$ and $\alpha 5\alpha 5\alpha 6$. Data from $\alpha 1(\text{IV})$, $\alpha 4(\text{IV})$ and $\alpha 6(\text{IV})$ were chosen to represent the three heterotrimers respectively (Fig. 2).

$\alpha 1(\text{IV})$ and $\alpha 2(\text{IV})$ were ubiquitously expressed in all ocular basement membranes at all developmental stages tested, with the strongest labeling intensity detected in the lens capsule. $\alpha 1(\text{IV})$ and $\alpha 2(\text{IV})$ were already present at E12.5 and labeled the entire lens capsule and tunica vasculosa lentis (the vascular network immediately adjacent to the posterior surface of the lens capsule) throughout development (Figs. 2 and 3). Both the epithelium and endothelium of the cornea were labeled, as were the pigmented and non-pigmented epithelia of the ciliary body and the pigmented epithelia of the iris (Fig. 4). In the iridocorneal angle, $\alpha 1(\text{IV})$ and $\alpha 2(\text{IV})$ were detected in the episcleral vein and the developing trabecular meshwork. In the vitreous and inner retina, $\alpha 1(\text{IV})$ and $\alpha 2(\text{IV})$ antibodies strongly and consistently labeled the hyaloid vasculature whereas the labeling intensity of the inner limiting membrane was weaker and decreased after E16.5 (Figs. 2 and 5). Bruch's membrane is an organized extracellular matrix structure outside the retina, with basement

membranes secreted from the RPE (retinal pigment epithelium) and the vascular endothelial cells of the choriocapillaris, which define the innermost and outermost layers respectively. $\alpha 1(\text{IV})$ and $\alpha 2(\text{IV})$ both exhibited network-like labeling in Bruch's membrane, consistent with the endothelial basement membrane of the choriocapillaris (Fig. 6). The intimate association of the RPE and choroidal basement membranes prevented unequivocal determination of labeling in the RPE basement membranes. However, high magnification confocal microscopy revealed complete co-localization with laminin, suggesting that $\alpha 1(\text{IV})$ and $\alpha 2(\text{IV})$ were expressed both in RPE and choroidal basement membranes (data not shown). Overall, $\alpha 1(\text{IV})$ and $\alpha 2(\text{IV})$ always co-localized and were present in all basement membranes of the developing eye.

$\alpha 3(\text{IV})$ and $\alpha 4(\text{IV})$ had the most restricted distribution and underwent the most dynamic changes during ocular development. They were first detected at E14.5 as a faint labeling of Bruch's membrane at the posterior pole of the eye (Fig. 2). By E18.5, the intensity of the signal had increased and the signal spread peripherally to include all of Bruch's membrane, implying an increase in both the level and distribution of $\alpha 3(\text{IV})$ and $\alpha 4(\text{IV})$ expression. Labeling in Bruch's membrane was unlike the network-like labeling of the choriocapillaris detected with $\alpha 1(\text{IV})$ and $\alpha 2(\text{IV})$ but instead was a single, tight line indicating the RPE basement membrane. Similar to the posterior pole of the eye, a central-to-peripheral expansion of labeling was detected in the lens capsule. Labeling was first detected in the anterior pole of the lens capsule but then spread peripherally in early postnatal eyes (Fig. 3). By P4, the entire anterior and peripheral lens was positive for $\alpha 3(\text{IV})$ and $\alpha 4(\text{IV})$. Postnatal labeling was also detected in the corneal endothelium. In summary, localization of $\alpha 3(\text{IV})$ and $\alpha 4(\text{IV})$ was temporally dynamic and relatively restricted compared to other type IV collagen isoforms.

$\alpha 5(\text{IV})$ and $\alpha 6(\text{IV})$ were present in most ocular basement membranes. $\alpha 5(\text{IV})$ co-localized both with $\alpha 3(\text{IV})/\alpha 4(\text{IV})$ and with $\alpha 6(\text{IV})$ and contributes to two different heterotrimers, $\alpha 3\alpha 4\alpha 5$ and $\alpha 5\alpha 5\alpha 6$. Therefore, only $\alpha 6(\text{IV})$ labeling is specific to the $\alpha 5\alpha 5\alpha 6$ heterotrimer. $\alpha 5(\text{IV})$ and $\alpha 6(\text{IV})$ were already detected in the entire lens capsule and the inner limiting membrane at E12.5 and labeling remained throughout development. Corneal epithelium was labeled at E14.5 followed by corneal endothelial labeling at E16.5 (Fig. 2). Relatively intense labeling was detected adjacent to the pigmented and non-pigmented epithelia of the ciliary body and throughout the iridocorneal angle with the exception of the episcleral vein, which was labeled by $\alpha 1(\text{IV})$ and $\alpha 2(\text{IV})$ (Fig. 4). The vitreous and inner retina revealed further notable differences between $\alpha 5\alpha 5\alpha 6$ compared to $\alpha 1\alpha 1\alpha 2$. The inner limiting membrane labeled relatively stronger with $\alpha 5(\text{IV})$ and $\alpha 6(\text{IV})$; however, no labeling was observed in the hyaloid vasculature or the tunica vasculosa lentis for either $\alpha 5(\text{IV})$ or $\alpha 6(\text{IV})$ indicating that only the $\alpha 1\alpha 1\alpha 2$ heterotrimer is present there (Figs. 3 and 5). A second notable difference was observed in the RPE contribution of Bruch's membrane. After transient detection of $\alpha 6(\text{IV})$ in the anterior and peripheral Bruch's membrane at E12.5 and E14.5, $\alpha 5(\text{IV})$, but not $\alpha 6(\text{IV})$, was detected in the basal RPE indicating that $\alpha 5(\text{IV})$ in Bruch's membrane is part of the $\alpha 3\alpha 4\alpha 5$ heterotrimer. Neither $\alpha 5(\text{IV})$ nor $\alpha 6(\text{IV})$ was present in the choriocapillaris (Fig. 6). Taken together, $\alpha 5(\text{IV})$ was detected in all basement membranes except for the episcleral vein, hyaloid vasculature, tunica vasculosa lentis and choriocapillaris indicating that $\alpha 1\alpha 1\alpha 2$ is the only heterotrimer localized to the vasculature.

3. Discussion

Our data demonstrate the distribution pattern of all six collagen IV isoforms. Localization of these isoforms is consistent with formation of the three heterotrimers: $\alpha 1\alpha 1\alpha 2$, $\alpha 3\alpha 4\alpha 5$ and $\alpha 5\alpha 5\alpha 6$ and the results are summarized in Table 1. Different heterotrimers are proposed to have different physical characteristics. For example, compared to $\alpha 1\alpha 1\alpha 2$ heterotrimers, $\alpha 3\alpha 4\alpha 5$ heterotrimers have a greater number of inter- and intra-molecular cross-links. As a result, $\alpha 3\alpha 4\alpha 5$ heterotrimers are predicted to be stronger and more resistant to proteolysis, while $\alpha 1\alpha 1\alpha 2$ heterotrimers are predicted to be more elastic and susceptible to physical or proteolytic breakdown. Others have suggested that isoform switching reflects a tissue's changing demands for mechanical strength or elasticity (Kabosova et al., 2007; Kelley et al., 2002). While potentially correct, it is important to consider that the physical properties of the basement membranes might not be entirely dictated by the collagen network and contributions of other basement membrane proteins should be considered. Additionally, differential isoform usage may reflect not only physical properties but also other important biological properties; for example, cell-matrix interactions or differential sequestration/release of growth factors during key developmental windows. Comprehensive studies of basement membrane composition, physical properties (Candiello et al., 2007) and intracellular signaling through development, especially during times of isoform changes, will be important for understanding the significance of these events.

To better understand which cell types and basement membranes might be responsible for the pathology in collagen IV-related diseases, we paid particular attention to which heterotrimers localized to sites of pathogenesis. The lens capsule is a specialized basement membrane enveloping the entire lens, and its components are produced and secreted by lens epithelial cells. Mice with mutation of *Col4a1* or *Col4a2* have lens abnormalities including cataracts and lens vacuoles (Favor et al., 2007; Gould et al., 2007; Van Agtmael et al., 2005). Similarly, Alport syndrome patients with mutations in *COL4A3*, *COL4A4*, or *COL4A5* are frequently reported with cataracts, and ruptured or weakened lens capsule that results in lenticonus (Arnott et al., 1966; Colville and Savige, 1997). Consistent with these phenotypes, all three heterotrimers are detected in the developing lens.

In addition to these cell autonomous defects, the lens is important for normal development of the ocular anterior segment. Dysgenesis of the anterior segment, and specifically the ocular drainage structures in the iridocorneal angle strongly predispose to elevated intraocular pressure and glaucoma. Glaucoma is one of leading causes of blindness and is often associated with elevated intraocular pressure. *Col4a1* mutant mice have anterior segment dysgenesis and elevated intraocular pressure (Gould et al., 2007), which model human developmental glaucoma. Recently a *COL4A1* mutation was identified in a family with anterior segment dysgenesis (Axenfeld-Reiger Anomaly) and glaucoma (Sibon et al., 2007). One possibility is that anterior segment dysgenesis is secondary to primary lens defects. *Col4a1* mutation causes endoplasmic reticulum stress in lens epithelial cells (Gould et al., 2007), which might influence production or secretion of growth factors. Alternatively, structural differences in mutant lens capsules could lead to aberrant sequestration or release of important signaling molecules (Neptune et al., 2003; Wang et al., 2008). Absence of anterior segment dysgenesis and glaucoma in Alport patients might suggest that the timing

of the lens defects is important, the mechanism is different (either functional defects in lens epithelium or structural defects of lens capsule) or that the lens is not the primary site of pathogenesis. The presence of $\alpha 1\alpha 1\alpha 2$, but not $\alpha 3\alpha 4\alpha 5$ heterotrimer, in the developing iridocorneal angle might suggest that iridocorneal angle, and not the lens, is a primary site of pathogenesis. Understanding the location of the primary insult will greatly facilitate identification of the underlying cellular mechanism. We have developed a *Col4a1* conditional mutant allele that will enable us to test the effect of the mutant protein when expressed in a tissue specific manner.

In the retina, developmental or progressive loss of retinal ganglion cells can contribute to optic nerve hypoplasia or glaucoma respectively. The inner limiting membrane is adjacent to retinal ganglion cells and is important for retinal ganglion cell survival during development (Halfter et al., 2005). *Col4a1* mutant mice have inner limiting membrane abnormalities, and increased loss of retinal ganglion cells during development appears to contribute to optic nerve hypoplasia (D. J. Dilworth manuscript in preparation). Although currently untested, inner limiting membrane abnormalities could also give rise to retinal ganglion cell death in response to elevated intraocular pressure, and thus predispose to glaucoma. The signal intensity of $\alpha 1\alpha 1\alpha 2$ in the inner limiting membrane decreased with age and $\alpha 5\alpha 5\alpha 6$ appeared to be the predominant heterotrimer postnatally (Fig. 2). This suggests that $\alpha 1\alpha 1\alpha 2$ might be important during development but that $\alpha 5\alpha 5\alpha 6$ might be more important in the mature inner limiting membrane.

Bruch's membrane is an important anatomical structure for retinal diseases and has two distinct basement membranes. The innermost layer of Bruch's membrane is a basal lamina secreted by the RPE cells and the outermost layer is a basal lamina secreted by the vascular endothelium of the choriocapillaris. Similar to the distribution in human Bruch's membrane (Chen et al., 2003), $\alpha 1\alpha 1\alpha 2$ is the only heterotrimer present in the choroidal vasculature, and $\alpha 3\alpha 4\alpha 5$ molecules are present in the RPE basement membrane. Most Alport syndrome patients have dot-and-fleck retinopathy, however, little is known about the pathogenic mechanisms. Depending on genetic context, *Col4a1* mutant mice have clinical, histological and molecular similarities to human patients with age-related macular degeneration (D. B. Gould manuscript in preparation). Macular degeneration is the leading cause of blindness in the elderly. Understanding both the cellular mechanism(s) and the relative contribution of RPE versus choroidal vasculature to diseases could provide important insights into prevention and treatment of this common cause of blindness.

Here, we examined the differential localization of type IV collagens during ocular development with special attention to sites relevant for human ocular diseases. Understanding the timing and localization of different isoforms will help elucidate mechanism(s) of ocular diseases caused by collagen IV mutations. Using this comprehensive and detailed analysis as a template, we will further refine the primary site (s) of *Col4a1*-related ocular pathology using tissue specific expression of a conditional mutant allele. These studies have direct relevance to several developmental and progressive diseases including optic nerve hypoplasia, glaucoma, and macular degeneration that collectively contribute to vision loss in millions of patients worldwide.

4. Experimental procedures

4.1. Tissue preparation

All animals used in this study were inbred derivations of C57BL/6J mice obtained from the Jackson Laboratory (Bar Harbor, ME). All experiments conducted were in accordance with the Institutional Animal Care and Use Committee guidelines. Two reference points were used to determine developmental stage: for embryonic samples, the time when a vaginal plug was observed was designated as embryonic day 0.5 (E0.5); for postnatal samples, the date of birth was designated as postnatal day 0 (P0). Embryos at E12.5, E14.5, E16.5 and E18.5 were harvested from timed pregnant females. For both embryonic and postnatal samples, heads were quickly excised, washed 3 times in cold PBS and incubated in 4% sucrose for 4 h. Samples were then embedded in OCT compound (Sakura Finetek USA Inc. Torrance, CA) and frozen with dry-ice/ethanol bath and stored at -20°C . All tissue sections were obtained by cryosectioning in the horizontal plane at a thickness of 8–10 μm using a Leica CM1900 cryostat (Rankin Biomedical Corp. Holly, MI).

4.2. Hematoxylin & eosin staining

Cryosections were fixed in 100% ethanol for 10 min, incubated in hematoxylin (Richard–Allan Scientific, Kalamazoo, MI) for 2 min. Samples were then washed sequentially in H_2O for 30 s, Clarifier I (Richard–Allan Scientific, Kalamazoo, MI) for 1 min, H_2O for 1 min, Bluing Reagent (Richard–Allan Scientific, Kalamazoo, MI) for 1 min, H_2O for 1 min and finally 95% ethanol for 30 s. The sections were counterstained with eosin Y (Fisher Scientific, Fair Lawn, NJ) for 2.5 min, washed two times each in 100% ethanol and xylene, and then cover slipped using Permount mounting media (Fisher Scientific, Fair Lawn, NJ). Images were obtained using an AxioImager M1 microscope equipped with an AxioCam ICc3 color digital camera and AxioVision software (Zeiss, Germany). Post-acquisition images were processed in Photoshop CS3 (Adobe).

4.3. Immunohistochemistry

Cryosections were fixed in acetone for 10 min, rinsed briefly with TT buffer (50 mM Tris–HCl, pH 7.4, 0.1% Tween 20) and then subjected to two different antigen retrieval methods. All antibodies gave consistent labeling with both antigen retrieval methods and so we proceeded with the method that gave the best signal-to-noise ratio for each antibody. For retrieval of $\alpha 1(\text{IV})$, $\alpha 2(\text{IV})$ and $\alpha 5(\text{IV})$ antigens, sections were incubated in acid solution (0.1 M KCl/HCl, pH 1.5) for 10 min. For retrieval of $\alpha 3(\text{IV})$, $\alpha 4(\text{IV})$ and $\alpha 6(\text{IV})$ antigens, sections were incubated for 20 min in 6 M urea containing 0.1 M glycine (pH 3.5). After antigen retrieval, sections were washed 3 times in TT buffer, incubated for 1 h in blocking buffer (10% normal goat serum and 2 mg/ml bovine serum albumin in Tris buffer), and then incubated for 2 h in TT buffer containing rabbit anti-laminin antibody (dilution 1:2000, Abcam Inc, MA) and/or collagen $\alpha(\text{IV})$ chain-specific antibody: H11 (dilution 1:200), H22 (dilution 1:20), H31 (dilution 1:50), RH42 (dilution 1:100), H53 (dilution 1:100), B66 (dilution 1:50) (Shigei Medical Research Institute, Japan). After washing three times with TT buffer, samples were incubated in a dark, humid chamber for 40 min with appropriate secondary antibodies: Alexa Fluor 594 anti-rabbit IgG for laminin or Alexa Fluor 488 anti-rat IgG for collagen IV antibodies (dilution 1:2000, Molecular Probes, OR). Samples were

washed three times with TT buffer and cover slipped with Vectashield Hardset mounting media with DAPI (Vector Laboratories Inc. CA). Images were captured using either a LSM5 PASCAL confocal microscope with Neofluor objective lens, or an AxioImager M1 microscope equipped with an AxioCam MRm digital camera and AxioVision software (Zeiss, Germany). Post-acquisition images were processed in Photoshop CS3 (Adobe).

4.4. Antibodies

Monoclonal antibodies against each of the six collagen IV isoforms were purchased from Shigei Medical Research Institute (Japan) and have been described previously (Ninomiya et al., 1995). Briefly, rats or mice were immunized with synthetic peptides to collagen IV NCI or the triple helical domain. Lymphocytes from the immunized animals were harvested and fused with mouse myeloma cells. Supernatants from hybridoma cultures were screened with ELISA and indirect immunofluorescence. We tested ten antibodies: one each for $\alpha 1(\text{IV})$ and $\alpha 3(\text{IV})$ and two each for $\alpha 2(\text{IV})$, $\alpha 4(\text{IV})$, $\alpha 5(\text{IV})$ and $\alpha 6(\text{IV})$. Where two antibodies were available for a protein, data were always consistent and we chose the antibody that gave the strongest signal-to-noise ratio in our hands. We chose rat antibodies H11, H22, H31, RH42, H53 and B66 for $\alpha 1(\text{IV})$ through $\alpha 6(\text{IV})$ respectively.

Acknowledgements

We would like to thank Dr. Geoffrey Lambright for advice and assistance with confocal microscopy and Dr. Richard Libby for critical review of the manuscript. This work was supported by grants from That Man May See (X.B. and D.B.G.), Alberta Heritage Foundation for Medical Research (D.J.D.), the Heart and Stroke Foundation of Canada (D.J.D.), the Larry L. Hillblom Foundation (Y.C.W. and D.B.G.), a core grant from the National Eye Institute (EY02162) and a Research To Prevent Blindness Unrestricted Grant.

Abbreviations

BM	basement membrane
DIC	differential interference contrast
ILM	inner limiting membrane
ICA	iridocorneal angle
RPE	retinal pigment epithelium

References

- Arnott EJ, Crawford MD, Toghil PJ. Anterior lenticonus and Alport's syndrome. *Br. J. Ophthalmol.* 1966; 50(7):390–403. [PubMed: 5947587]
- Barker DF, Hostikka SL, Zhou J, Chow LT, Oliphant AR, Gerken SC, Gregory MC, Skolnick MH, Atkin CL, Tryggvason K. Identification of mutations in the COL4A5 collagen gene in Alport syndrome. *Science.* 1990; 248(4960):1224–1227. [PubMed: 2349482]
- Borza DB, Bondar O, Ninomiya Y, Sado Y, Naito I, Todd P, Hudson BG. The NC1 domain of collagen IV encodes a novel network composed of the alpha 1, alpha 2, alpha 5, and alpha 6 chains in smooth muscle basement membranes. *J. Biol. Chem.* 2001; 276(30):28532–28540. [PubMed: 11375996]
- Borza DB, Bondar O, Todd P, Sundaramoorthy M, Sado Y, Ninomiya Y, Hudson BG. Quaternary organization of the goodpasture autoantigen, the alpha 3(IV) collagen chain. Sequestration of two

- cryptic autoepitopes by intrapromoter interactions with the alpha4 and alpha5 NC1 domains. *J. Biol. Chem.* 2002; 277(42):40075–40083. [PubMed: 12193605]
- Breedveld G, de Coo IF, Lequin MH, Arts WF, Heutink P, Gould DB, John SW, Oostra B, Mancini GM. Novel mutations in three families confirm a major role of COL4A1 in hereditary porencephaly. *J. Med. Genet.* 2006; 43(6):490–495. [PubMed: 16107487]
- Candiello J, Balasubramani M, Schreiber EM, Cole GJ, Mayer U, Halfter W, Lin H. Biomechanical properties of native basement membranes. *FEBS J.* 2007; 274(11):2897–2908. [PubMed: 17488283]
- Chen L, Miyamura N, Ninomiya Y, Handa JT. Distribution of the collagen IV isoforms in human Bruch's membrane. *Br. J. Ophthalmol.* 2003; 87(2):212–215. [PubMed: 12543754]
- Chugh KS, Sakhuja V, Agarwal A, Jha V, Joshi K, Datta BN, Gupta A, Gupta KL. Hereditary nephritis (Alport's syndrome)—clinical profile and inheritance in 28 kindreds. *Nephrol. Dial. Transplant.* 1993; 8(8):690–695. [PubMed: 8414153]
- Cochat P, Guibaud P, Garcia Torres R, Roussel B, Guarner V, Larbre F. Diffuse leiomyomatosis in Alport syndrome. *J. Pediatr.* 1988; 113(2):339–343. [PubMed: 3294362]
- Colville DJ, Savige J. Alport syndrome. A review of the ocular manifestations. *Ophthalmic Genet.* 1997; 18(4):161–173. [PubMed: 9457747]
- Colville D, Savige J, Branley P, Wilson D. Ocular abnormalities in thin basement membrane disease. *Br. J. Ophthalmol.* 1997a; 81(5):373–377. [PubMed: 9227202]
- Colville D, Savige J, Morfis M, Ellis J, Kerr P, Agar J, Fasset R. Ocular manifestations of autosomal recessive Alport syndrome. *Ophthalmic Genet.* 1997b; 18(3):119–128. [PubMed: 9361309]
- de Vries LS, Koopman C, Groenendaal F, Van Schooneveld M, Verheijen FW, Verbeek E, Witkamp TD, van der Worp HB, Mancini G. COL4A1 mutation in two preterm siblings with antenatal onset of parenchymal hemorrhage. *Ann. Neurol.* 2009; 65(1):12–18. [PubMed: 19194877]
- Favor J, Gloeckner CJ, Janik D, Klempt M, Neuhauser-Klaus A, Pretsch W, Schmahl W, Quintanilla-Fend L. Type IV procollagen missense mutations associated with defects of the eye, vascular stability, the brain, kidney function and embryonic or postnatal viability in the mouse, *Mus musculus*: an extension of the Col4a1 allelic series and the identification of the first two Col4a2 mutant alleles. *Genetics.* 2007; 175(2):725–736. [PubMed: 17179069]
- Gould DB, Smith RS, John SW. Anterior segment development relevant to glaucoma. *Int. J. Dev. Biol.* 2004; 48(8–9):1015–1029. [PubMed: 15558492]
- Gould DB, Phalan FC, Breedveld GJ, van Mil SE, Smith RS, Schimenti JC, Aguglia U, van der Knaap MS, Heutink P, John SW. Mutations in Col4a1 cause perinatal cerebral hemorrhage and porencephaly. *Science.* 2005; 308(5725):1167–1171. [PubMed: 15905400]
- Gould DB, Phalan FC, van Mil SE, Sundberg JP, Vahedi K, Massin P, Bousser MG, Heutink P, Miner JH, Tournier-Lasserre E, John SW. Role of COL4A1 in small-vessel disease and hemorrhagic stroke. *N. Engl. J. Med.* 2006; 354(14):1489–1496. [PubMed: 16598045]
- Gould DB, Marchant JK, Savinova OV, Smith RS, John SW. Col4a1 mutation causes endoplasmic reticulum stress and genetically modifiable ocular dysgenesis. *Hum. Mol. Genet.* 2007; 16(7):798–807. [PubMed: 17317786]
- Gunwar S, Ballester F, Noelken ME, Sado Y, Ninomiya Y, Hudson BG. Glomerular basement membrane. Identification of a novel disulfide-cross-linked network of alpha3, alpha4, and alpha5 chains of type IV collagen and its implications for the pathogenesis of Alport syndrome. *J. Biol. Chem.* 1998; 273(15):8767–8775. [PubMed: 9535854]
- Halfter W, Willem M, Mayer U. Basement membrane-dependent survival of retinal ganglion cells. *Invest. Ophthalmol. Vis. Sci.* 2005; 46(3):1000–1009. [PubMed: 15728558]
- Hasegawa H, Naito I, Nakano K, Momota R, Nishida K, Taguchi T, Sado Y, Ninomiya Y, Ohtsuka A. The distributions of type IV collagen alpha chains in basement membranes of human epidermis and skin appendages. *Arch. Histol. Cytol.* 2007; 70(4):255–265. [PubMed: 18296826]
- Heidet L, Cai Y, Sado Y, Ninomiya Y, Thorner P, Guicharnaud L, Boye E, Chauvet V, Solal LC, Beziau A, Torres RG, Antignac C, Gubler MC. Diffuse leiomyomatosis associated with X-linked Alport syndrome: extracellular matrix study using immunohistochemistry and in situ hybridization. *Lab. Invest.* 1997; 76(2):233–243. [PubMed: 9042160]

- Hostikka SL, Eddy RL, Byers MG, Hoyhtya M, Shows TB, Tryggvason K. Identification of a distinct type IV collagen alpha chain with restricted kidney distribution and assignment of its gene to the locus of X chromosome-linked Alport syndrome. *Proc. Natl. Acad. Sci. U. S. A.* 1990; 87(4): 1606–1610. [PubMed: 1689491]
- Hostikka SL, Tryggvason K. The complete primary structure of the alpha 2 chain of human type IV collagen and comparison with the alpha 1(IV) chain. *J. Biol. Chem.* 1988; 263(36):19488–19493. [PubMed: 3198637]
- Hudson BG, Reeders ST, Tryggvason K. Type IV collagen: structure, gene organization, and role in human diseases. Molecular basis of Goodpasture and Alport syndromes and diffuse leiomyomatosis. *J. Biol. Chem.* 1993; 268(35):26033–26036. [PubMed: 8253711]
- Jacobs M, Jeffrey B, Kriss A, Taylor D, Sa G, Barratt TM. Ophthalmologic assessment of young patients with Alport syndrome. *Ophthalmology.* 1992; 99(7):1039–1044. [PubMed: 1495781]
- Kabosova A, Azar DT, Bannikov GA, Campbell KP, Durbeej M, Ghohestani RF, Jones JC, Kenney MC, Koch M, Ninomiya Y, Patton BL, Paulsson M, Sado Y, Sage EH, Sasaki T, Sorokin LM, Steiner-Champliand MF, Sun TT, Sundarraj N, Timpl R, Virtanen I, Ljubimov AV. Compositional differences between infant and adult human corneal basement membranes. *Invest. Ophthalmol. Vis. Sci.* 2007; 48(11):4989–4999. [PubMed: 17962449]
- Kaufmann, MH. *The Atlas of Mouse Development.* Elsevier Academic Press; London, UK: 2005.
- Kelley PB, Sado Y, Duncan MK. Collagen IV in the developing lens capsule. *Matrix Biol.* 2002; 21(5):415–423. [PubMed: 12225806]
- Kuhn K. Basement membrane (type IV) collagen. *Matrix Biol.* 1995; 14(6):439–445. [PubMed: 7795882]
- Leinonen A, Mariyama M, Mochizuki T, Tryggvason K, Reeders ST. Complete primary structure of the human type IV collagen alpha 4(IV) chain. Comparison with structure and expression of the other alpha (IV) chains. *J. Biol. Chem.* 1994; 269(42):26172–26177. [PubMed: 7523402]
- Mariyama M, Leinonen A, Mochizuki T, Tryggvason K, Reeders ST. Complete primary structure of the human alpha 3(IV) collagen chain. Coexpression of the alpha 3(IV) and alpha 4(IV) collagen chains in human tissues. *J. Biol. Chem.* 1994; 269(37):23013–23017.
- Nakano K, Naito I, Momota R, Sado Y, Hasegawa H, Ninomiya Y, Ohtsuka A. The distribution of type IV collagen alpha chains in the mouse ovary and its correlation with follicular development. *Arch. Histol. Cytol.* 2007; 70(4):243–253. [PubMed: 18296825]
- Neptune ER, Frischmeyer PA, Arking DE, Myers L, Bunton TE, Gayraud B, Ramirez F, Sakai LY, Dietz HC. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. *Nat. Genet.* 2003; 33(3):407–411. [PubMed: 12598898]
- Ninomiya Y, Kagawa M, Iyama K, Naito I, Kishiro Y, Seyer JM, Sugimoto M, Oohashi T, Sado Y. Differential expression of two basement membrane collagen genes, COL4A6 and COL4A5, demonstrated by immunofluorescence staining using peptide-specific monoclonal antibodies. *J. Cell Biol.* 1995; 130(5):1219–1229. [PubMed: 7657706]
- Plaisier E, Gribouval O, Alamowitch S, Mougnot B, Prost C, Verpont MC, Marro B, Desmettre T, Cohen SY, Rouillet E, Dracon M, Fardeau M, VanAgtmael T, Kerjaschki D, Antignac C, Ronco P. COL4A1 mutations and hereditary angiopathy, nephropathy, aneurysms, and muscle cramps. *N. Engl. J. Med.* 2007; 357(26):2687–2695. [PubMed: 18160688]
- Risteli J, Schuppan D, Glanville RW, Timpl R. Immunochemical distinction between two different chains of type IV collagen. *Biochem. J.* 1980; 191(2):517–522. [PubMed: 6165353]
- Sado Y, Kagawa M, Kishiro Y, Sugihara K, Naito I, Seyer JM, Sugimoto M, Oohashi T, Ninomiya Y. Establishment by the rat lymph node method of epitope-defined monoclonal antibodies recognizing the six different alpha chains of human type IV collagen. *Histochem. Cell Biol.* 1995; 104(4):267–275. [PubMed: 8548560]
- Saito K, Naito I, Seki T, Oohashi T, Kimura E, Momota R, Kishiro Y, Sado Y, Yoshioka H, Ninomiya Y. Differential expression of mouse alpha5(IV) and alpha6(IV) collagen genes in epithelial basement membranes. *J. Biochem.* 2000; 128(3):427–434. [PubMed: 10965041]
- Schlotzer-Schrehardt U, Dietrich T, Saito K, Sorokin L, Sasaki T, Paulsson M, Kruse FE. Characterization of extracellular matrix components in the limbal epithelial stem cell compartment. *Exp. Eye Res.* 2007; 85(6):845–860. [PubMed: 17927980]

- Semina EV, Bosenko DV, Zinkevich NC, Soules KA, Hyde DR, Vihtelic TS, Willer GB, Gregg RG, Link BA. Mutations in laminin alpha 1 result in complex, lens-independent ocular phenotypes in zebrafish. *Dev. Biol.* 2006; 299(1):63–77. [PubMed: 16973147]
- Sibon I, Coupry I, Menegon P, Bouchet JP, Gorry P, Burgelin I, Calvas P, Orignac I, Dousset V, Lacombe D, Orgogozo JM, Arveiler B, Goizet C. COL4A1 mutation in Axenfeld–Rieger anomaly with leukoencephalopathy and stroke. *Ann. Neurol.* 2007; 62(2):177–184. [PubMed: 17696175]
- Soininen R, Haka-Risku T, Prockop DJ, Tryggvason K. Complete primary structure of the alpha 1-chain of human basement membrane (type IV) collagen. *FEBS Lett.* 1987; 225(1–2):188–194. [PubMed: 3691802]
- Streeten BW, Robinson MR, Wallace R, Jones DB. Lens capsule abnormalities in Alport's syndrome. *Arch. Ophthalmol.* 1987; 105(12):1693–1697. [PubMed: 3689194]
- Timpl R, Wiedemann H, van Delden V, Furthmayr H, Kuhn K. A network model for the organization of type IV collagen molecules in basement membranes. *Eur. J. Biochem.* 1981; 120(2):203–211. [PubMed: 6274634]
- Urabe N, Naito I, Saito K, Yonezawa T, Sado Y, Yoshioka H, Kusachi S, Tsuji T, Ohtsuka A, Taguchi T, Murakami T, Ninomiya Y. Basement membrane type IV collagen molecules in the choroid plexus, pia mater and capillaries in the mouse brain. *Arch. Histol. Cytol.* 2002; 65(2):133–143. [PubMed: 12164337]
- Vahedi K, Boukobza M, Massin P, Gould DB, Tournier-Lasserre E, Bousser MG. Clinical and brain MRI follow-up study of a family with COL4A1 mutation. *Neurology.* 2007a; 69(16):1564–1568. [PubMed: 17938367]
- Vahedi K, Kubis N, Boukobza M, Arnoult M, Massin P, Tournier-Lasserre E, Bousser MG. Col4a1 mutation in a patient with sporadic, recurrent intracerebral hemorrhage. *Stroke.* 2007b; 38(5):1461–1464. [PubMed: 17379824]
- Van Agtmael T, Schlotzer-Schrehardt U, McKie L, Brownstein DG, Lee AW, Cross SH, Sado Y, Mullins JJ, Poschl E, Jackson IJ. Dominant mutations of Col4a1 result in basement membrane defects which lead to anterior segment dysgenesis and glomerulopathy. *Hum. Mol. Genet.* 2005; 14(21):3161–3168. [PubMed: 16159887]
- Wang X, Harris RE, Bayston LJ, Ashe HL. Type IV collagens regulate BMP signalling in *Drosophila*. *Nature.* 2008; 455(7209):72–77. [PubMed: 18701888]
- Zenker M, Aigner T, Wendler O, Tralau T, Muntefering H, Fenski R, Pitz S, Schumacher V, Royer-Pokora B, Wuhl E, Cochat P, Bouvier R, Kraus C, Mark K, Madlon H, Dotsch J, Rascher W, Maruniak-Chudek I, Lennert T, Neumann LM, Reis A. Human laminin beta2 deficiency causes congenital nephrosis with mesangial sclerosis and distinct eye abnormalities. *Hum. Mol. Genet.* 2004; 13(21):2625–2632. [PubMed: 15367484]
- Zenker M, Pierson M, Jonveaux P, Reis A. Demonstration of two novel LAMB2 mutations in the original Pierson syndrome family reported 42 years ago. *Am. J. Med. Genet. A.* 2005; 138(1):73–74. [PubMed: 16097004]
- Zhou J, Ding M, Zhao Z, Reeders ST. Complete primary structure of the sixth chain of human basement membrane collagen, alpha 6(IV). Isolation of the cDNAs for alpha 6(IV) and comparison with five other type IV collagen chains. *J. Biol. Chem.* 1994; 269(18):13193–13199. [PubMed: 8175748]




Fig. 1. Basement membranes in the developing eye. (A) A cross-section of a P4 eye stained with Hematoxylin & Eosin showing the major ocular structures. (B) An immediate adjacent section labeled with a pan-laminin antibody revealing basement membranes in the ocular tissue. BrM: Bruch's membrane; CB: ciliary body; CE: corneal epithelium; CN: corneal endothelium; HV: hyaloid vasculature; ICA: iridocorneal angle; ILM: inner limiting membrane; LC: lens capsule; TVL: tunica vasculosa lentis. Scale bar: 100 μ m.




Fig. 2. Differential distribution of type IV collagens in the developing mouse eye. Ocular distribution of collagen IV isoforms was determined using monoclonal antibodies to each isoform at advancing stages of development (the age for each row is indicated in the upper right corner of panels A–F). $\alpha 1(\text{IV})$ and $\alpha 2(\text{IV})$ always co-localized, were ubiquitously present, and are represented by $\alpha 1(\text{IV})$ labeling (A–F). $\alpha 3(\text{IV})$ and $\alpha 4(\text{IV})$ always co-localized, had developmentally dynamic expression, and are represented by $\alpha 4(\text{IV})$ labeling (G–L). $\alpha 5(\text{IV})$ co-localized both with $\alpha 3/\alpha 4(\text{IV})$ and with $\alpha 6(\text{IV})$ (M–R). Together $\alpha 1(\text{IV})$, $\alpha 4(\text{IV})$ and $\alpha 6(\text{IV})$ represent the $\alpha 1\alpha 1\alpha 2$, $\alpha 3\alpha 4\alpha 5$ and $\alpha 5\alpha 5\alpha 6$ heterotrimers respectively. A summary of the data can be found in Table 1. Scale bars: E12.5–E14.5: 200 μm ; E16.5–P4: 100 μm .




Fig. 3.

Collagen IV distribution in the lens. All three collagen IV heterotrimers were detected in the postnatal lens capsule. (A and D) At P4, the posterior lens capsule was labeled with laminin (red). Vascular endothelial cells of the tunica vasculosa lentis labeled with DAPI (blue), and their basement membranes labeled with laminin. (B) $\alpha 1(\text{IV})$ antibody (green) labeled both the lens capsule and the tunica vasculosa lentis and co-localized with laminin (yellow signal in C). (E) $\alpha 6(\text{IV})$ antibody labeled the lens capsule but did not co-localize with laminin in the tunica vasculosa lentis (F). $\alpha 4(\text{IV})$ antibody revealed spatially restricted localization to the anterior lens capsule (G and K) but not the posterior lens capsule (J and N) with a transition near the equatorial zone (arrowheads) of the lens (H, I, L, and M). CN: Corneal endothelium; LC: Lens capsule. Scale bar: 50 μm .




Fig. 4. Collagen IV distribution in the anterior segment. (A) A differential interference contrast image (DIC) shows anatomical structures of the iridocorneal angle at P4. (B) Labeling with a $\alpha 2(\text{IV})$ antibody was positive in all basal lamina of the anterior segment and in the differentiating trabecular meshwork of the iridocorneal angle. (C) In contrast, $\alpha 4(\text{IV})$ labeling was restricted only to the corneal endothelium. (D) $\alpha 6(\text{IV})$ labeling was nearly ubiquitous and strongly labeled the developing trabecular meshwork and all basal lamina, with the exception of the episcleral vessel. AC: anterior chamber; CJ: conjunctiva; CN: corneal endothelium; EV: episcleral vessel; IR: iris; NPE: non-pigmented epithelium of the ciliary body; PE: pigmented epithelium of the ciliary body; TM: trabecular meshwork. Scale bar: 20 μm .




Fig. 5. Collagen IV distribution in the inner retina. (A, D, G) Laminin labeling (red) of the inner retina at P4 revealed basement membranes of the hyaloid vasculature (HV) and inner limiting membrane (ILM). (B) $\alpha 1(\text{IV})$ antibody strongly labeled the hyaloid vasculature in the inner retina and weakly labeled the inner limiting membrane (overlay with laminin in C). (E) $\alpha 4(\text{IV})$ was absent from both hyaloid vasculature and inner limiting membrane (overlay with laminin in F). (H) $\alpha 6(\text{IV})$ was present only in the inner limiting membrane (overlay with laminin in I). Nuclei were stained with DAPI (blue). Scale bar: 50 μm .




Fig. 6. Collagen IV distribution in the outer retina. (A, D, G) DIC images of eyes from P4 mice. (B) $\alpha 1(\text{IV})$ labeled Bruch's membrane in a network-like pattern consistent with the basement membranes of the choroidal vasculature. (E) $\alpha 4(\text{IV})$ labeled Bruch's membrane in an even, continuous linear pattern consistent with the basement membrane of the retinal-pigmented epithelium. (H) $\alpha 6(\text{IV})$ labeling was negative in the outer retina. Merged images (C, F, and I) are shown in the bottom panels. Scale bar: 50 μm .

Table 1

Summary of type IV collagen isoform distribution in the developing mouse eye.

Col IV Isoform	Age	Ocular basement membranes									
		Conjunctiva	Corneal epithelium	Corneal endothelium	Ciliary body & ICA	Lens capsule	ILM	Hyaloid vessels	Bruch's membrane		
								RPE	Choroicapillaris		
α1/α2(IV)	E12.5	N/A	++	N/A	N/A	++	++	++	++	++	
	E14.5	N/A	+	+	N/A	+++	++	+++	++	++	
	E16.5	N/A	+	+	+	+++	+	+++	++	++	
	E18.5	+	+	+	+	+++	+	+++	++	++	
α3/α4(IV)	P1	++	++	++	++	+++	+	+++	++	++	
	P4	++	++	++	++	+++	+	+++	++	++	
	E12.5	N/A	-	N/A	N/A	-	-	-	±	-	
	E14.5	N/A	-	-	N/A	-	-	-	+	-	
α5(IV)	E16.5	N/A	-	-	-	-	-	-	+	-	
	E18.5	-	-	±	-	±	-	-	++	-	
	P1	-	-	++	-	+++	-	-	++	-	
	P4	-	-	+++	-	+++	-	-	++	-	
α6(IV)	E12.5	N/A	-	N/A	N/A	++	++	++	+	-	
	E14.5	N/A	+	±	N/A	+++	++	+++	+	-	
	E16.5	N/A	+	+	++	+++	++	+++	-	-	
	E18.5	+	+	+	++	+++	++	+++	-	-	
α5(IV)	P1	++	++	+++	+++	+++	++	+++	++	-	
	P4	++	++	+++	+++	+++	++	+++	++	-	
	E12.5	N/A	-	N/A	N/A	++	++	++	+	-	
	E14.5	N/A	+	±	N/A	+++	++	+++	+	-	
α5(IV)	E16.5	N/A	+	+	++	+++	++	+++	-	-	
	E18.5	+	+	+	++	+++	++	+++	-	-	
	P1	++	++	+++	+++	+++	++	+++	-	-	
	P4	++	++	+++	+++	+++	++	+++	-	-	

Relative intensity of the fluorescent signal between tissues for each antibody is indicated as:

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

-, negative; ±, weak positive; +, positive; ++, strong positive; +++, strongest positive. ICA: iridocorneal angle; ILM: inner limiting membrane; N/A: not available; RPE: retinal pigment epithelium.

^aExpressed only at the posterior pole.

^bExpressed only at the anterior pole.